| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
New data reinforce Mirum's commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIVMARLI (maralixibat) and volixibat clinical programs will be shared during the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting®, taking place November 7-11, 2025, in Washington, D.C.
The presentations highlight Mirum's continued progress in expanding the scientific and clinical foundation for new approaches to treating adult and pediatric rare liver diseases, including new findings from the VANTAGE trial and real-world studies.
Posted In: MIRM
